Bio/pharmaceutical – why we use this term

Bio/pharmaceutical includes both small molecule drugs, peptide drugs and biologics (vaccines, cell or gene therapies, tissue growth factors, cytokines, monoclonal antibodies and therapeutic protein hormones). The term applies to companies that pursue both types of agents as well as the so-called biopharmaceutical companies who specialize in therapies based on protein agents.

Protein-based drugs refer to those biologics managed by the Center for Drug Evaluation and Research – tissue growth factors, cytokines, monoclonal antibodies and therapeutic protein hormones.

The work on protein-based drugs can be different at each stage of Discovery and Development.  The processes that are unique to the discovery and development of protein-based drugs change the success rates of some of the stages, most noticeable in Discovery, as well as the reasons for failure, and project cycle times.  In this website we will note those differences where they are known at least in a qualitative sense.

Bio/pharmaceutical includes both small molecule, peptide and protein-based drugs as well as other biologics. The term applies to companies that pursue both types of agents as well as the so-called biopharmaceutical companies who specialize in therapies based on biologics.


     

    We Appreciate Your Comments!


    six − 6 =